# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Argus Research analyst David Toung maintains Eli Lilly and Co (NYSE:LLY) with a Buy and raises the price target from $770 to...
Pfizer seeks to expands its reach with 'Pfizer for All,' offering direct-to-consumer medical services, including COVID ...
Google DeepMind reveals its AlphaFold 3, which specializes in molecular predictions for proteins, DNA, RNA, and drug molecules.
Legendary hedge fund manager Stanley Druckenmiller made right bets at the right time. He came to fame for earning Soros $10B ov...
FDA's advisory committee meeting on June 10, 2024, discussing Eli Lilly's donanemab for early Alzheimer's.
-Reuters